Knees next for Mesoblast

By Dylan Bushell-Embling
Tuesday, 12 August, 2008

Preclinical trials conducted by Mesoblast [ASX: MSB] have shown that the company's adult stem cells are capable of regenerating damaged knee cartilage in a post-menopausal osteoarthritis large animal model.

A single injection of adult stem cells was able to repair and regenerate knee cartilage in ewes with well established osteoarthritis even though the cells were administered three months after initial joint damage.

This effect has yet to be demonstrated by any competing products on the market, the company said.

Mesoblast executive director Professor Silviu Itescu said the results meant the company would now target both post-menopausal and post-traumatic knee osteoarthritis for product commercialisation.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd